Our results suggest that tacrolimus protects podocytes during the progression of type 2 diabetic nephropathy, possibly ameliorating podocyte apoptosis by downregulating the expression of TRPC6. This evidence concerns the gene TRPC6 and type 2 diabetes nephropathy.